Zurcher Kantonalbank Zurich Cantonalbank Sells 343,899 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Zurcher Kantonalbank Zurich Cantonalbank reduced its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 92.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 29,440 shares of the company’s stock after selling 343,899 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Ionis Pharmaceuticals were worth $1,489,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in IONS. Tennessee Valley Asset Management Partners acquired a new position in Ionis Pharmaceuticals in the 4th quarter valued at $34,000. Peoples Bank KS acquired a new position in Ionis Pharmaceuticals during the 3rd quarter worth approximately $39,000. China Universal Asset Management Co. Ltd. raised its stake in Ionis Pharmaceuticals by 95.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,670 shares of the company’s stock worth $166,000 after buying an additional 1,795 shares during the period. Mitchell & Pahl Private Wealth LLC purchased a new stake in shares of Ionis Pharmaceuticals in the third quarter worth approximately $210,000. Finally, Sherbrooke Park Advisers LLC purchased a new stake in shares of Ionis Pharmaceuticals in the third quarter worth approximately $224,000. 93.86% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 23,501 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $49.37, for a total transaction of $1,160,244.37. Following the sale, the chief executive officer now directly owns 174,138 shares of the company’s stock, valued at approximately $8,597,193.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 23,501 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $49.37, for a total transaction of $1,160,244.37. Following the sale, the chief executive officer now directly owns 174,138 shares of the company’s stock, valued at approximately $8,597,193.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Elizabeth L. Hougen sold 2,125 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $49.54, for a total value of $105,272.50. Following the sale, the chief financial officer now directly owns 92,905 shares in the company, valued at $4,602,513.70. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,699 shares of company stock valued at $2,104,091. 2.65% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on IONS shares. Royal Bank of Canada upped their target price on Ionis Pharmaceuticals from $65.00 to $70.00 and gave the company an “outperform” rating in a report on Friday, January 26th. StockNews.com upgraded Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 24th. William Blair restated an “outperform” rating on shares of Ionis Pharmaceuticals in a research report on Tuesday, April 9th. Oppenheimer raised their price target on Ionis Pharmaceuticals from $72.00 to $75.00 and gave the company an “outperform” rating in a research report on Tuesday, April 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $60.00 price objective on shares of Ionis Pharmaceuticals in a research note on Tuesday, April 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.08.

Ionis Pharmaceuticals Stock Down 1.4 %

NASDAQ IONS opened at $41.84 on Friday. The company has a debt-to-equity ratio of 3.18, a current ratio of 5.90 and a quick ratio of 5.83. The stock has a market capitalization of $6.10 billion, a PE ratio of -16.34 and a beta of 0.39. Ionis Pharmaceuticals, Inc. has a 1 year low of $34.32 and a 1 year high of $54.44. The business’s 50-day moving average is $43.40 and its 200 day moving average is $47.23.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Wednesday, February 21st. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.72. The business had revenue of $325.00 million for the quarter, compared to analysts’ expectations of $176.01 million. Ionis Pharmaceuticals had a negative return on equity of 90.29% and a negative net margin of 46.32%. The business’s revenue was up 113.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.37) EPS. Sell-side analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.88 earnings per share for the current year.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.